Single-cell analysis reveals two distinct subsets of BCR-ABL+ stem cells from patients who achieved hematological remission after being subjected to TKI treatments, with one group enriched for a quiescent gene signature and the other enriched for MYC and proliferation-associated gene sets, suggesting clonally segregated CML LSCs may account for differential sensitivities to TKIs, which can impact treatment outcomes [168]. This evidence concerns the gene MYC and chronic myelogenous leukemia, BCR-ABL1 positive.